Xeris pharmaceuticals, inc. (XERS)
Income statement / Yearly
Dec'19Dec'18Dec'17
Net sales

1,627

0

-

Grant and other income

1,095

2,423

1,540

Cost of goods sold

1,603

0

-

Service revenue

-

-

16

Cost of revenue

-

-

4

Gross profit (loss)

1,119

2,423

1,552

Operating expenses
Research and development

60,438

40,654

20,166

Selling, general and administrative

63,061

21,113

8,015

Total operating expenses

123,499

61,767

28,181

Loss from operations

-122,380

-59,344

-26,629

Other income (expense)
Interest and other income

2,813

1,613

124

Interest expense

7,163

2,500

-2

Change in fair value of warrants

-692

-196

-46

Other expense

-

-

1

Total other income (expense)

-3,658

-736

75

Net loss before provision for/benefit from income taxes

-126,038

-60,080

-

Provision for/benefit from income taxes

-458

0

-

Net loss

-125,580

-60,080

-26,554

Other comprehensive income (loss), net of tax
Unrealized gains on investments

93

-52

-

Foreign currency translation adjustments

2

0

-

Unrealized gains (losses) on investments

-

-

0

Comprehensive loss

-125,485

-60,132

-26,554

Net loss per common share - basic and diluted

-4.81

-4.99

-13.09

Weighted average common shares outstanding, basic and diluted

26,110

12,045

2,028